Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...

Japan-based Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy developed by Ionis ...

Ionis Pharmaceuticals is licensing out another experimental medicine, entering an agreement with Ono Pharmaceutical that ...

OSAKA, Japan I March 11, 2025 I Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “ONO”) announced that it has ...

Japanese drugmaker Ono (TYO: 4528) has entered into a license agreement with USA-based Ionis Pharmaceuticals (Nasdaq: IONS) ...

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report)’s stock price reached a new 52-week high on Tuesday after Truist Financial raised their price target on the stock from $60.00 to $76.00.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Protagonist Therapeutics (NASDAQ:PTGX – Free Report) had its price objective hoisted by Truist Financial from $60.00 to $76.00 in a research note released on Tuesday morning,Benzinga reports. The firm ...